Naltrexone withdrawal

Pro Research Analysisby

Searched over 200M research papers for "naltrexone withdrawal"

Analyzed relevant papers

Naltrexone Withdrawal: Insights from Recent Research

Introduction to Naltrexone and Opioid Withdrawal

Naltrexone is a medication used to manage opioid dependence by blocking the euphoric effects of opioids. However, its use can precipitate withdrawal symptoms in opioid-dependent individuals. This article synthesizes recent research on naltrexone-induced withdrawal, focusing on its management, severity, and implications for treatment protocols.

Naltrexone and Buprenorphine for Shortened Opioid Detoxification

Combining naltrexone with a short buprenorphine taper can effectively manage withdrawal symptoms during opioid detoxification. A study comparing two groups—one receiving naltrexone with buprenorphine (NB Group) and the other receiving buprenorphine followed by naltrexone (PB Group)—found that starting naltrexone on day 2 significantly reduced withdrawal symptoms after day 5. This combination was deemed safe and effective for shortening the duration of withdrawal symptoms .

Extended-Release Naltrexone and Withdrawal Management

Extended-release naltrexone (XR-NTX) has shown promise in preventing relapse in opioid-dependent patients. A phase 3 trial examined the efficacy of low-dose oral naltrexone combined with a brief buprenorphine taper for transitioning patients to XR-NTX. The study found comparable transition rates to XR-NTX across different regimens, with mild to moderate withdrawal symptoms reported. This suggests that structured outpatient settings with ancillary medications can effectively manage withdrawal during the transition to XR-NTX .

Precipitated Withdrawal and Noradrenergic Hyperactivity

Naltrexone can precipitate withdrawal symptoms in opioid-dependent individuals, which are often associated with noradrenergic hyperactivity. A study involving methadone-dependent subjects found that naltrexone-induced withdrawal significantly increased plasma concentrations of free MHPG, a marker of noradrenergic activity. This supports the hypothesis that central noradrenergic hyperactivity plays a role in the expression of withdrawal symptoms .

Rapid Induction onto Naltrexone Using Naloxone-Precipitated Withdrawal

Naloxone-precipitated withdrawal has been explored as a method for rapid induction onto naltrexone. In a study involving methadone-dependent patients, repeated naloxone injections induced less intense withdrawal symptoms over time, allowing for a transition to naltrexone maintenance within 48 hours. This method demonstrated the potential for rapid detoxification and initiation of naltrexone treatment .

Clinical Implications and Management Strategies

The management of naltrexone-induced withdrawal requires careful consideration of dosing strategies and patient compliance. Studies have shown that when taken as directed, naltrexone does not precipitate withdrawal. However, non-compliance or misuse, such as crushing extended-release formulations, can lead to withdrawal symptoms and reduced euphoric effects of opioids . Additionally, early control of withdrawal symptoms may predict better treatment outcomes, emphasizing the need for individualized transition protocols .

Conclusion

Naltrexone-induced withdrawal presents challenges in the treatment of opioid dependence, but recent research offers valuable insights into effective management strategies. Combining naltrexone with buprenorphine, using structured outpatient settings, and understanding the role of noradrenergic hyperactivity are key to improving patient outcomes. Rapid induction methods and adherence to prescribed dosing can further enhance the efficacy of naltrexone in preventing relapse and supporting long-term recovery.

Sources and full results

Most relevant research papers on this topic

Naltrexone shortened opioid detoxification with buprenorphine.

Naltrexone combined with buprenorphine effectively shortens opioid detoxification and is an acceptable and safe treatment for inducing naltrexone maintenance.

RCTHighly Cited

1999·

73citations

·A. Umbricht et al.

Drug and alcohol dependence·

DOI

Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users

Naltrexone in MSN does not precipitate withdrawal when taken intact, but when crushed, it mitigates but does not eliminate the euphorigenic effects of crushed morphine sulfate in non-dependent recreational opioid users.

Systematic Review

2018·

3citations

·B. Setnik et al.

Current Medical Research and Opinion·

DOI

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.

A 7-day detoxification protocol with naltrexone alone or naltrexone + buprenorphine provided similar rates of induction to extended-release injectable naltrexone as placebo, with higher opioid abstinence during transition and lower post-XR-NTX withdrawal scores

RCTLarge Human Trial

2018·

41citations

·A. Bisaga et al.

Drug and alcohol dependence·

DOI

Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone

Early opioid withdrawal changes can indicate treatment response and help adjust transition protocols for individual patients.

Observational Study

2018·

6citations

·P. Mannelli et al.

The American Journal on Addictions·

DOI

Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.

Extended release naltrexone may overcome opioid blockade in some cases, resulting in vulnerability to naltrexone-induced withdrawal.

Case Report

2008·

44citations

·M. Fishman

Addiction·

DOI

Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity.

Naltrexone precipitates opiate withdrawal in methadone-dependent individuals, suggesting that noradrenergic hyperactivity may be a functional mechanism for at least part of the opiate withdrawal syndrome.

RCT

1984·

55citations

·Dennis S. Charney et al.

Life sciences·

DOI

Naloxone‐precipitated withdrawal: A method for rapid induction onto naltrexone

Naloxone-precipitated withdrawal can effectively detoxify and induct patients onto naltrexone within 48 hours, allowing transition from opiate dependence to maintenance within 48 hours.

Non-RCTHighly Cited

1977·

95citations

·R. Resnick et al.

Clinical Pharmacology & Therapeutics·

DOI

A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months.

Precipitated withdrawal under anesthesia is more effective than standard inpatient withdrawal for heroin users, leading to a significant reduction in heroin use and morphine concentration over 12 months.

RCT

2002·

41citations

·C. Mcgregor et al.

Drug and alcohol dependence·

DOI

Withdrawal syndrome caused by naltrexone in opioid abusers

Naltrexone-induced hyperacute withdrawal in opioid-dependent patients can cause severe agitation, with no relationship found between naltrexone dose and symptoms.

Observational Study

2014·

34citations

·H. Hassanian‐Moghaddam et al.

Human & Experimental Toxicology·

DOI

Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone

Short-term inpatient treatment for opioid use disorder is associated with high relapse rates, and medication-assisted treatment is recommended to reduce these risks.

RCTLarge Human TrialHighly Cited

2017·

95citations

·E. Nunes et al.

Journal of substance abuse treatment·

DOI

Try another search

non-insulin hypoglycemic agents

arteries definition

is weed a flower

armour thyroid dosage

supplements for mood

medication for stop smoking